AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30709557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aprepitant therapy (aprepitant plus dexamethasone and tropisetron)
Number of subjects: 100
Study 30709557 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (dexamethasone and tropisetron)
Number of subjects: 100
Study 29057429 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label suggestions
Number of subjects: 92
Study 29057429 — intervention group
Group type: COMPARATOR
Intervention: No suggestions (Control)
Number of subjects: 92
Study 26921267 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) as an add-on to treatment as usual (TAU)
Number of subjects: 180
Study 26921267 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational programme (FibroQoL) as an add-on to treatment as usual (TAU)
Number of subjects: 180
Study 26921267 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 180
Study 24521531 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal family and school program (EBPIs) offered to families in 6th grade and one of three school-based programs in 7th grade.
Number of subjects: 0
Study 24521531 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based programs used in conjunction with school-based programs.
Number of subjects: 0
Study 22127729 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate treatment group
Number of subjects: 52
Study 22127729 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 52
Study 21406947 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple dissatisfaction (34.8%)
Number of subjects: 65
Study 21406947 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction-oriented coping style
Number of subjects: 65
Study 17370037 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 over 1 h on day 1 followed by ifosfamide 5 g/m2 divided over days 1 and 2 (2.5 g/m2/day over 1 h), recycled every 21 days with prophylactic G-CSF administration from day 3 until a neutrophil count >10,000/microl.
Number of subjects: 71
Study 16011127 — intervention group
Group type: EXPERIMENTAL
Intervention: FloSeal (FS) packing
Number of subjects: 18
Study 16011127 — intervention group
Group type: COMPARATOR
Intervention: Thrombin-soaked gelatin foam
Number of subjects: 18
Study 12177583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg/day
Number of subjects: 278
Study 12177583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 80 mg/day
Number of subjects: 278
Study 12177583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 160 mg/day
Number of subjects: 278
Study 12177583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 12177583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (all doses)
Number of subjects: 278
Study 12177583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 278
Study 9539583 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 44
Study 9539583 — intervention group
Group type: COMPARATOR
Intervention: Milrinone
Number of subjects: 44
Study 8586834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (10 mg/kg twice a day orally) with exogenous angiotensin II (1 ng/kg per min intravenously)
Number of subjects: 0
Study 8586834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (10 mg/kg twice a day orally) with frusemide (40 mg/day orally for 2 days)
Number of subjects: 0
Study 8586834 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin (10 mg/kg twice a day orally)
Number of subjects: 0
Study 2710909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (N = 30)
Number of subjects: 77
Study 2710909 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (N = 27)
Number of subjects: 77
Study 2710909 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment, N = 20)
Number of subjects: 77
Study 902626 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and hydroflumethiazide (HFM)
Number of subjects: 52
Study 902626 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and HFM
Number of subjects: 52
Study 902626 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg daily)
Number of subjects: 52
Study 902626 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 52
Study 31282392 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve mobilization (FNM)
Number of subjects: 68
Study 31282392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatic nerve mobilization (SNM)
Number of subjects: 68
Study 31282392 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 68
Study 31542980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhaler (4 mg deliverable)
Number of subjects: 26
Study 31542980 — intervention group
Group type: COMPARATOR
Intervention: Nicotine-free inhaler
Number of subjects: 26
Study 31542980 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived nicotine administration
Number of subjects: 26
Study 31542980 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected nicotine administration
Number of subjects: 26
Study 28100177 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane-remifentanil anesthesia
Number of subjects: 103
Study 28100177 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil anesthesia
Number of subjects: 103
Study 25291152 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic metoprolol tartrate 100 mg oral dose
Number of subjects: 35
Study 24026317 — intervention group
Group type: EXPERIMENTAL
Intervention: Social networking intervention via Facebook groups over 12 weeks
Number of subjects: 112
Study 24026317 — intervention group
Group type: COMPARATOR
Intervention: Control group (general health information)
Number of subjects: 112
Study 24026317 — intervention group
Group type: EXPERIMENTAL
Intervention: Social networking intervention
Number of subjects: 112
Study 24026317 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 21796867 — intervention group
Group type: EXPERIMENTAL
Intervention: Biointo (beta-glucan, inositol and digestive enzymes)
Number of subjects: 50
Study 21796867 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 50
Study 19182682 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 104
Study 19182682 — intervention group
Group type: COMPARATOR
Intervention: Antidyspeptic drugs usage
Number of subjects: 104
Study 17109784 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder pillow
Number of subjects: 40
Study 17109784 — intervention group
Group type: EXPERIMENTAL
Intervention: All pillow conditions
Number of subjects: 40
Study 14998048 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest SpinBrush Pro with redesigned bristle head
Number of subjects: 44
Study 14998048 — intervention group
Group type: COMPARATOR
Intervention: Crest SpinBrush Pro
Number of subjects: 44
Study 15908730 — intervention group
Group type: EXPERIMENTAL
Intervention: Tot'hema
Number of subjects: 42
Study 10476342 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization
Number of subjects: 58
Study 8731850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefteram
Number of subjects: 123
Study 8731850 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 123
Study 2036693 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 micrograms.kg‐1 fentanyl via a peripheral venous cannula (Group 1)
Number of subjects: 250
Study 2036693 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg.kg‐1 atropine iv one minute before fentanyl (Group 3)
Number of subjects: 250
Study 2036693 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg.kg‐1 morphine im one hour before fentanyl (Group 4)
Number of subjects: 250
Study 2036693 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg midazolam po one hour before fentanyl (Group 5)
Number of subjects: 250
Study 2036693 — intervention group
Group type: COMPARATOR
Intervention: saline (Group 2)
Number of subjects: 250
Study 7272896 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected environment-prophylactic antibiotic (PEPA)
Number of subjects: 51
Study 7272896 — intervention group
Group type: COMPARATOR
Intervention: Control group (CYVADIC without PEPA)
Number of subjects: 51
Study 30496024 — intervention group
Group type: EXPERIMENTAL
Intervention: Long HIIT (3 bouts of 4 min at 90% of vVO2peak, interspersed by 3 min of recovery at 60% of vVO2peak, 21 min total)
Number of subjects: 10
Study 30496024 — intervention group
Group type: COMPARATOR
Intervention: Short HIIT (29 bouts of 30s at vVO2peak, interspersed by 30s of passive recovery, 29 min total)
Number of subjects: 10
Study 30496024 — intervention group
Group type: COMPARATOR
Intervention: MICT (21 min at 70% of vVO2peak)
Number of subjects: 10
Study 28270491 — intervention group
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish contact lens in flat sleeping position
Number of subjects: 12
Study 28270491 — intervention group
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish contact lens in 30° head-up sleeping position
Number of subjects: 12
Study 28270491 — intervention group
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish contact lens after 24 hours of wear
Number of subjects: 12
Study 26797215 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 328
Study 26797215 — intervention group
Group type: COMPARATOR
Intervention: Protease Inhibitors (ATV/r, DRV/r combined)
Number of subjects: 328
Study 24440643 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 145
Study 24440643 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and range of movement exercises (SS)
Number of subjects: 145
Study 24440643 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 145
Study 22410598 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Cessation program
Number of subjects: 39
Study 22410598 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study 20795797 — intervention group
Group type: EXPERIMENTAL
Intervention: doc.com
Number of subjects: 0
Study 20795797 — intervention group
Group type: EXPERIMENTAL
Intervention: WebEncounter
Number of subjects: 0
Study 20795797 — intervention group
Group type: EXPERIMENTAL
Intervention: doc.com + WebEncounter
Number of subjects: 0
Study 20795797 — intervention group
Group type: COMPARATOR
Intervention: Control group (WebOSCE assessment only)
Number of subjects: 0
Study 17627015 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon Cancer Risk Counseling (CCRC)
Number of subjects: 176
Study 17627015 — intervention group
Group type: COMPARATOR
Intervention: General Health Counseling (GHC)
Number of subjects: 176
Study 15818607 — intervention group
Group type: EXPERIMENTAL
Intervention: Jail diversion programs (3 pre-booking and 3 post-booking)
Number of subjects: 0
Study 15818607 — intervention group
Group type: COMPARATOR
Intervention: Non-diverted groups
Number of subjects: 0
Study 11887193 — intervention group
Group type: EXPERIMENTAL
Intervention: sibutramine 10mg
Number of subjects: 86
Study 11887193 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 86
Study 9861551 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (IR; 20-40 mg)
Number of subjects: 10
Study 9861551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate (SR; 20-40 mg)
Number of subjects: 10
Study 9861551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8907212 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention
Number of subjects: 0
Study 8907212 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 0
Study 2924517 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 11
Study 2924517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31491479 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Performing Sites (HPS)
Number of subjects: 2100
Study 31491479 — intervention group
Group type: COMPARATOR
Intervention: Low-Performing Sites (LPS)
Number of subjects: 2100
Study 31491479 — intervention group
Group type: EXPERIMENTAL
Intervention: HPS
Number of subjects: 2100
Study 31491479 — intervention group
Group type: COMPARATOR
Intervention: LPS
Number of subjects: 2100
Study 30907346 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated sandplay therapy in addition to routine training
Number of subjects: 44
Study 30907346 — intervention group
Group type: COMPARATOR
Intervention: Routine training (Control)
Number of subjects: 44
Study 27803120 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with CAN at DCCT closeout
Number of subjects: 1262
Study 27803120 — intervention group
Group type: COMPARATOR
Intervention: Participants without CAN at DCCT closeout
Number of subjects: 1262
Study 27803120 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐R variation as a continuous variable
Number of subjects: 1262
Study 26829443 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol) 20,000 IU/wk
Number of subjects: 511
Study 26829443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study 23855840 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate
Number of subjects: 24
Study 23855840 — intervention group
Group type: EXPERIMENTAL
Intervention: herbal mouthwash
Number of subjects: 24
Study 23855840 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 24
Study 22172564 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 121
Study 22172564 — intervention group
Group type: COMPARATOR
Intervention: Individual adolescent focused therapy (AFT)
Number of subjects: 121
Study 19183412 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bromfenac
Number of subjects: 72
Study 19183412 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone
Number of subjects: 72
Study 19183412 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (bromfenac and betamethasone)
Number of subjects: 72
Study 19183412 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 72
Study 17964038 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous revascularization during index hospitalization
Number of subjects: 1891
Study 17964038 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cardiogenic shock
Number of subjects: 1891
Study 17964038 — intervention group
Group type: COMPARATOR
Intervention: Patients without shock
Number of subjects: 1891
Study 15688962 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice (sodium bicarbonate, dual-phase dentifrice containing calcium and phosphate)
Number of subjects: 108
Study 15688962 — intervention group
Group type: COMPARATOR
Intervention: Control Dentifrice (commercial hydrated silica dentifrice)
Number of subjects: 108
Study 15688962 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice
Number of subjects: 108
Study 12181221 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-twin transfusion syndrome recipient fetuses
Number of subjects: 136
Study 12181221 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated monochorionic diamniotic twins
Number of subjects: 136
Study 12181221 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital heart disease prevalence in twin-twin transfusion syndrome
Number of subjects: 136
Study 12181221 — intervention group
Group type: COMPARATOR
Intervention: Congenital heart disease prevalence in singletons
Number of subjects: 136
Study 9855322 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 19
Study 9855322 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 19
Study 9855322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9855322 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 350 mg
Number of subjects: 19
Study 7861791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (1.0 g/kg, divided into two equal doses given 75 minutes apart)
Number of subjects: 37
Study 7861791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar schedule as ethanol group)
Number of subjects: 37
Study 2510276 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil, 150 micrograms t.i.d. for 12 weeks
Number of subjects: 30
Study 2510276 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil, 200 micrograms b.i.d. for 12 weeks
Number of subjects: 30
Study 2510276 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil
Number of subjects: 30
Study 2510276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 799958 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic propranolol
Number of subjects: 0
Study 799958 — intervention group
Group type: COMPARATOR
Intervention: Dextrorotatory propranolol
Number of subjects: 0
Study 31325802 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin administration
Number of subjects: 115
Study 31325802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 28406806 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one mentorship for HIV and TB care (8 hours a week for 9 months)
Number of subjects: 40
Study 28406806 — intervention group
Group type: COMPARATOR
Intervention: No clinical mentorship (control group)
Number of subjects: 40
Study 28406806 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site clinical mentorship
Number of subjects: 40
Study 25931433 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 88
Study 25931433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 23883828 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial disc replacement (Discover artificial disc)
Number of subjects: 136
Study 23883828 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical decompression and fusion (ACDF)
Number of subjects: 136
Study 23883828 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 136
Study 21972626 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture and acupoint injection with Neostigmine (in addition to conventional western medicine)
Number of subjects: 116
Study 21972626 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicine (control group)
Number of subjects: 116
Study 21972626 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture and acupoint injection with Neostigmine
Number of subjects: 116
Study 18390974 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded cardiac rehabilitation including stress management, increased physical training, staying at a 'patient hotel' and cooking sessions
Number of subjects: 224
Study 18390974 — intervention group
Group type: COMPARATOR
Intervention: Usual cardiac rehabilitation
Number of subjects: 224
Study 15995103 — intervention group
Group type: COMPARATOR
Intervention: Urine leukotriene B4 (LTB4) levels in patients with FMF (12 patients)
Number of subjects: 36
Study 15995103 — intervention group
Group type: COMPARATOR
Intervention: Urine leukotriene B4 (LTB4) levels in patients with other forms of acute right lower abdominal pain (including appendicitis, urologic disorders, nonspecific abdominal pain)
Number of subjects: 36
Study 15995103 — intervention group
Group type: COMPARATOR
Intervention: Urine leukotriene B4 (LTB4) levels in healthy control subjects (18 volunteers)
Number of subjects: 36
Study 12135284 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) at cumulative doses of 3.75 mg/kg for 5 days
Number of subjects: 84
Study 12135284 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) at cumulative doses of 7.5 mg/kg for 5 days
Number of subjects: 84
Study 12135284 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) at cumulative doses of 15.0 mg/kg for 5 days
Number of subjects: 84
Study 10407512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exposure to a 60 Hz, 28.3 microT magnetic field
Number of subjects: 24
Study 10407512 — intervention group
Group type: COMPARATOR
Intervention: Continuous exposure to a 60 Hz, 28.3 microT magnetic field
Number of subjects: 24
Study 10407512 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 24
Study 7751890 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate with cisplatin
Number of subjects: 0
Study 7751890 — intervention group
Group type: COMPARATOR
Intervention: Etoposide with cisplatin
Number of subjects: 0
Study 2265164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.5% to 0.75%)
Number of subjects: 70
Study 2265164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (with epinephrine)
Number of subjects: 70
Study 2265164 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 70
Study 367414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 0
Study 367414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31255890 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversalis Fascia Plane Block (TFPB)
Number of subjects: 70
Study 31255890 — intervention group
Group type: COMPARATOR
Intervention: Standard multimodal analgesia (routine paracetamol and tramadol PCA in addition to diclophenac sodium as rescue analgesia)
Number of subjects: 70
Study 29192967 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP-VA (Tailored Activity Program)
Number of subjects: 160
Study 29192967 — intervention group
Group type: COMPARATOR
Intervention: Control (telephone-based dementia education)
Number of subjects: 160
Study 26401826 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐DeNT Oral Topical Powder
Number of subjects: 46
Study 26401826 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 46
Study 25329470 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory women's health groups intervention with monthly meetings and a participatory learning and action cycle.
Number of subjects: 6275
Study 25329470 — intervention group
Group type: COMPARATOR
Intervention: Usual perinatal care (Control group).
Number of subjects: 6275